Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

by Pluschnig Ursula, Bartsch Rupert, Hubalek Michael, Mlineritsch Brigitte, Fiegl Michael, Steger Günther G
Published 2011-08-01

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

by Locker Gottfried J, Altorjai Gabriela, Sevelda Ursula, Hussian Dagmar, Pluschnig Ursula, Wenzel Catharina, Bartsch Rupert, Mader Robert, Zielinski Christoph C, Steger Guenther G
Published 2006-03-01

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

by Locker Gottfried J, Altorjai Gabriela, Koestler Wolfgang, Sevelda Ursula, Pluschnig Ursula, Hussian Dagmar, Wenzel Catharina, Bartsch Rupert, Mader Robert, Zielinski Christoph C, Steger Guenther G
Published 2006-03-01

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

by Rottenfusser Andrea, Mader Robert M, Rudas Margaretha, Gampenrieder Simon P, Bago-Horvath Zsuzsanna, Dubsky Peter, Pluschnig Ursula, De Vries Catharina, Bartsch Rupert, Wiltschke Christoph, Gnant Michael, Zielinski Christoph C, Steger Guenther G
Published 2009-10-01